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OBJECTIVEdTo evaluate whether etiologic diabetes type is associated with the degree of
albuminuria in children with diabetes.
RESEARCH DESIGN AND METHODSdSEARCH is an observational, longitudinal
study of children with diabetes. Youth with newly diagnosed diabetes were classified according
to diabetes autoantibody (DAA) status and presence of insulin resistance. We defined insulin
resistance as an insulin sensitivity score ,25th percentile for the United States general youth
population. DAA status was based on positivity for the 65-kD isoform of glutamate decarboxylase
and insulinoma-associated protein 2 antigens. The four etiologic diabetes type groups were as
follows: DAA+/insulin-sensitive (IS) (n = 1,351); DAA+/insulin-resistant (IR) (n = 438); DAA2/IR
(n = 379); andDAA2/IS (n = 233). Urinary albumin:creatinine ratio (UACR)wasmeasured from a
random urine specimen. Multivariable regression analyses assessed the independent relationship
between the four diabetes type groups and magnitude of UACR.
RESULTSdAdjustedUACRmeans across the four groupswere as follows: DAA+/IS = 154mg/mg;
DAA+/IR = 137 mg/mg; DAA2/IR = 257 mg/mg; and DAA2/IS = 131 mg/mg (P , 0.005). Only
DAA2/IR was significantly different. We performed post hoc multivariable regression analysis re-
stricted to the two IR groups to explore the contribution of DAA status and insulin sensitivity
(continuous) to the difference in UACR between the IR groups. Only insulin sensitivity was signif-
icantly associated with UACR (b = 20.54; P, 0.0001).
CONCLUSIONSdIn youth with diabetes, the DAA2/IR group had a greater UACR than all
other groups, possibly because of the greatermagnitude of insulin resistance. Further exploration
of the relationships between severity of insulin resistance, autoimmunity, and albuminuria in
youth with diabetes is warranted.
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P revious reports suggested that theclinical course and factors contrib-uting to the development and pro-
gression of diabetic nephropathy did not
differ by diabetes type and that diabetic
nephropathy was preceded by albumin-
uria that worsened over time (1,2). More
recent data have further elucidated the
natural history of diabetic kidney disease.
In the absence of albuminuria, a signifi-
cant number of people with diabetes, es-
pecially type 2, still develop a decline in
glomerular filtration rate (3,4). Thus,
there may be identifiable differences in
the natural history of nephropathy inher-
ent to the underlying diabetes type. Mul-
tiple pediatric diabetes cohorts have
found a higher prevalence of albuminuria
and progressive kidney failure in youth
with a clinical diagnosis of type 2 diabetes
than with type 1 diabetes (5–7). Such data
suggest that insulin resistance, a key com-
ponent of the pathophysiology of type 2
diabetes, may be an important contribu-
tor to diabetic nephropathy in youth with
diabetes.
The epidemic of overweight and obe-
sity has made it increasingly difficult to
clinically diagnose diabetes type, because
insulin resistance and autoimmunity of-
ten coexist (8,9). Cohort studies of youth
with type 1 diabetes have found a sig-
nificant increase in microvascular and
macrovascular diseases in those with con-
current insulin resistance (10–12). The
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prevalence of albuminuria in insulin-
resistant (IR) individuals with type 1
diabetes has not been compared with indi-
viduals with type 2 diabetes. Thus, the role
of autoimmunity and insulin resistance
across the spectrum of diabetes types and
the risk for microvascular complications
warrant investigation. Herein, we investi-
gate the magnitude of albuminuria accord-
ing to the status of autoimmunity and
insulin resistance in youth with newly di-




The SEARCH for Diabetes in Youth Study
is a multicenter, observational study of
youth with incident diabetes who are
followed-up longitudinally. A detailed
description of study methods has been
published previously (13). In brief,
SEARCH is an ongoing study that began
in 2001 to conduct population-based as-
certainment of cases of diabetes in youth
younger than 20 years of age. The study
protocol was reviewed and approved by
local institutional review boards that had
jurisdiction over the local study popula-
tions. Cases were ascertained from geo-
graphically defined populations in Ohio,
Colorado, SouthCarolina, andWashington,
among enrollees in several health plans
in California and Hawaii, and Indian
Health Service beneficiaries from four
American Indian populations. Youth iden-
tified with incident nonsecondary diabetes
were invited to a baseline study visit. Self-
reported race and ethnicity were collected
using the 2000 United States Census
questions (14).
Sample selection, design, and
measurements
This is a cross-sectional analysis explor-
ing the association between diabetes eti-
ologic group and the magnitude of
albuminuria. Inclusion criteria included
having a baseline visit during which
fasting blood was drawn, urine was col-
lected, and anthropometric measure-
ments were taken. These were used to
measure diabetes autoantibodies (DAAs)
and covariates used to calculate the in-
sulin sensitivity score (waist circumfer-
ence, triglycerides [TG], hemoglobin
A1c [HbA1c]) and to assess urine albu-
min:creatinine ratio (UACR). Individuals
using ACE inhibitors or angiotensin re-
ceptor blockers were excluded from these
analyses (n = 38).
The study visit included measure-
ment of waist circumference using the
National Health and Nutrition Examina-
tion Survey protocol (15), systolic blood
pressure, diastolic blood pressure, height,
and weight, as previously described (16).
Height and weight were measured to cal-
culate BMI (kg/m2), which was then con-
verted to z-scores using the standard
Centers for Disease Control and Preven-
tion approach (17).
Blood and urine samples were ob-
tained under conditions of metabolic
stability, defined as no episodes of di-
abetic ketoacidosis in the preceding
month and the absence of fever and acute
infections. Urine was not collected from
girls who were menstruating. Participants
excluded from analysis because of miss-
ing urine sample (n = 1,064) had similar
sociodemographic characteristics as the
analyzed cohort (data not shown). Speci-
mens were processed locally and shipped
within 24 h to the central laboratory
(Northwest Lipid Metabolism and Dia-
betes Research Laboratories, Seattle,
WA). Measurements of serum choles-
terol, TG, and HDL cholesterol were per-
formed using Roche reagent on a Roche
Module P autoanalyzer (Roche Diagnostics,
Indianapolis, IN). HbA1c wasmeasured by a
dedicated ion-exchange high-performance
liquid chromatography instrument (TOSOH
Bioscience).
Random spot urine samples were
collected. Urinary creatinine was measured
by the Jaffemethod using Roche reagent on
the Roche Modular P autoanalyzer. Two
quality-control samples were analyzed in
each run, and the interassay coefficient of
variation was consistently ,2%. Urine
albumin was measured immunochemi-
cally using Siemens reagent on a Siemens
BNII nephelometer. The sensitivity of the
assay was also 0.2 mg/dL. The interassay
coefficient of variation is ,5% for the
high-level and ,6.5% for the low-level
quality-control sample. Albuminuria
was defined as a UACR $30 mg/mg as
recommended by the American Diabe-
tes Association guidelines (18) and Na-
tional Kidney Disease Outcomes Quality
Initiative (19).
Definitions of DAAs and insulin
sensitivity or insulin resistance
Blood samples taken at the baseline visit
were analyzed for the 65-kD isoform
of glutamate decarboxylase antibodies
(GADA) and insulinoma-associated
protein 2 antibodies (IA-2A) using the
National Institute of Diabetes and
Digestive and Kidney Diseases standard-
ized method (20). The cutoff values for
positivity were 33 units/mL for GADA
and 5 units/mL for IA-2A. The specificity
and sensitivity were 97 and 76%, respec-
tively, for GADA and 99 and 64%, respec-
tively, for IA-2A (20). DAA positivity
(DAA+) was defined by positive titers for
either GADA or IA-2A. Because many par-
ticipants were treated with insulin, analy-
sis of insulin autoantibodies was not
performed.
The insulin sensitivity score was cal-
culated from variables measured at the
study visit using the following equation:
Expf4:6472522 ð0:02032  ½waist; cmÞ
2 ð0:002350  ½TG;mg=dLÞ
2 ð0:09779  ½HbA1c;%Þg
This equation was developed and vali-
dated using direct measurements of
glucose disposal rate from euglycemic-
hyperinsulinemic clamps conducted
among 85 of the 2,401 SEARCH partici-
pants included in this report and 22
matched nondiabetic control subjects
(21). As previously reported, we defined
insulin resistance among SEARCH partic-
ipants in this study as an insulin sensitivity
score value,25th percentile for the United
States general youth population (insulin
sensitivity,8.15) (22).
Participants were assigned to one of
four diabetes etiologic groups, according
to the status of autoimmunity and insulin
resistance at their baseline visit. These
four groups were as follows: DAA+/
insulin-sensitive (IS); DAA+/IR; DAA2/
IR; and DAA2/IS.
Statistical analyses
Statistical analyses were performed using
SAS software version 9.1 (SAS Institute,
Cary, NC) and S-PLUS software version
6.0 (Insightful, Seattle,WA). Eachminority
group was limited in sample size; hence,
for the present report, all racial/ethnic
groups other than non-Hispanic white
were combined into a single “ethnic mi-
nority” category. The distribution of each
potential covariate was evaluated and,
when necessary, logarithmically trans-
formed for normalization of the distri-
bution. The means and percents of
covariates were compared across the
four etiologic groups using x2 and ANOVA
tests when appropriate. Multivariable re-
gression analyses assessed the relation-
ship between the four etiologic groups
and the magnitude of UACR. Both the
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Shapiro–Wilk test and Kolmogorov–
Smirnov test indicated that the residuals
did not deviate significantly from a nor-
mal distribution. A plot of residuals
against the predicted values of the out-
come variable found no evidence that
the variance of the residuals changed
across the range of predicted values. Co-
variates included in the model were age at
visit, sex, race/ethnicity, parental education
and insurance type, clinic site, diabetes
duration, HbA1c, systolic blood pressure
z-score, and BMI z-score. Results were con-
sidered significant if P , 0.05.
RESULTSdThe sociodemographic and
clinical characteristics of the 2,401 par-
ticipants, according to the four etiologic
groups, are depicted in Table 1. The eth-
nic minority group comprised of 323 His-
panics, 312 non-Hispanic blacks, 99
Asians/Pacific Islanders, and 23 Native
Americans/Alaska Natives. There were
significant differences across the four eti-
ologic groups for all covariates. The larg-
est differences were in the DAA2 /IR
group, which, in comparison with the
other three groups, demonstrated a pre-
ponderance of ethnic minorities and ele-
vated systolic blood pressure, diastolic
blood pressure, and TG levels. Elevated
UACR ($30 mg/mg) was prevalent in
16% of the DAA2/IR group, which was
significantly higher than that of all other
groups (P = 0.0007).
Multivariable analysis suggested that
the etiologic groups significantly con-
tributed to the variability of UACR (P =
0.004). The adjusted mean UACR for the
DAA2/IR group was significantly higher
than those of the other three groups (Ta-
ble 2). All other pairwise comparisons
were nonsignificant (data not shown).
To explore reasons for the difference
in UACR between the two IR groups, we
performed a post hoc t test on the means
of the insulin sensitivity scores and
found them to be significantly different
(P, 0.0001). We then assessed the con-
tribution of DAA status and insulin sen-
sitivity to the difference in UACR
between the two IR groups by per-
forming a post hoc multivariable analysis
restricted to the IR participants. The regres-
sion equation used the original model but
incorporated DAA status and insulin sensi-
tivity (continuous) in place of the four eti-
ologic diabetes type groups. DAA status
was not statistically significant (b = 0.18;
P = 0.08), whereas insulin sensitivity was
significantly and inversely associated with
UACR (b = 20.54; P , 0.0001).
CONCLUSIONSdThis is the first
study to compare the magnitude of albu-
minuria in youth with diabetes classified
according to markers of the underlying
etiology of diabetes using measures of
autoimmunity and insulin resistance. We
found that in youthwith recently diagnosed
autoimmune-mediated diabetes, there was
no difference in UACR between those who
were IS compared with IR. There was, how-
ever, a significantly higher UACR in youth
without autoimmunity but with IR over all
other subgroups. There were significant
difference in covariates that could be con-
founders or mediators of the effect of etio-
logic subgroup; however, we statistically
controlled for this issue in our multivari-
able analysis. We hypothesized that the
difference in albuminuria between the two
IR groups could be attributable to a greater
severity of insulin resistance in the DAA2/IR
group. Post hoc analyses showed insulin
sensitivity to be significantly associated
with UACR in the IR groups.
Ourfinding that therewas no difference
in UACR between youth with autoimmune-
mediated diabetes who were IS compared
with IR was unexpected. The hypothesis
that insulin resistance in addition to auto-
immunity could increase the risk of micro-
vascular complications of diabetes was
proposed 20 years ago (23). Several studies
have since identified increases in both
microvascular and macrovascular com-
plications in persons with type 1 diabetes
with versus without insulin resistance
(11,12,24,25). It is difficult to compare
these studies with ours because of differ-
ences in study population and methodol-
ogies, especially our pediatric cohort with
newly diagnosed diabetes and estimation
of insulin resistance.
Table 1dSociodemographic and clinical characteristics of 2,401 youth with type 1 or type 2 diabetes according to etiologic group:
SEARCH for Diabetes in Youth Study
Variable*
DAA+/IS DAA+/IR DAA2/IR DAA2/IS
P†n = 1,351 n = 438 n = 379 n = 233
Age at diagnosis, years 9.3 (3.7) 12.9 (2.8) 13.8 (2.6) 9.3 (4.0) ,0.0001
Age at visit, years 10.3 (3.7) 14.1 (2.9) 14.9 (2.7) 10.4 (4.0) ,0.0001
Male, n (%) 729 (54) 221 (50) 145 (38) 137 (59) ,0.0001
Ethnicity, NHW n (%) 1,044 (77) 310 (71) 105 (28) 177 (76) ,0.0001
Diabetes duration, months 9.1 (5.8) 11.2 (6.7) 11.1 (6.9) 9.7 (6.2) ,0.0001‡
HbA1c, % 7.4 (1.2) 8.6 (2.1) 7.7 (2.3) 7.2 (1.4) ,0.0001‡
BMI z-score 0.3 (0.9) 1.2 (0.9) 2.0 (0.8) 0.2 (0.9) ,0.0001
Insulin sensitivity score 11.7 (1.2) 5.9(1.4) 3.8 (1.9) 11.9 (1.3) ,0.0001‡
SBP z-score 20.6 (0.9) 20.4 (0.9) 0.4 (1.1) 20.5 (0.9) ,0.0001
DBP z-score 0.1 (0.8) 0.2 (0.8) 0.5 (0.9) 0.1 (0.7) ,0.0001
Total cholesterol, mg/dL 158 (27) 168 (34) 175 (43) 157 (27) ,0.0001‡
TG, mg/dL (median [25th, 75th]) 52 (41, 66) 82 (60, 113) 122 (83, 189) 53 (43, 69) ,0.0001‡
HDL, mg/dL 56 (13) 51 (13) 42 (11) 55 (13) ,0.0001
LDL, mg/dL 90 (23) 98 (26) 104 (36) 90 (22) ,0.0001‡
UACR, mg/mg (median [25th, 75th]) 7 (5, 13) 6 (4, 13) 8 (5, 17) 7 (5, 12) 0.0146‡
UACR .30 mg/mg, n (%) 123 (9) 53 (12) 59 (16) 17 (7) 0.0007
DBP, diastolic blood pressure; NHW, non-Hispanic white; SBP, systolic blood pressure. *Mean (SD) unless otherwise noted. †P value across all four categories using
x2 test or ANOVA when appropriate. ‡Using log distribution for association tests.
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The significant difference in UACR
between the DAA+/IR and DAA2 /IR
groups also was unexpected. Post hoc
analysis restricted to the two IR groups
indicated that differences in the degree
of IS between the two groups was associ-
ated with the higher UACR in the DAA2/
IR group. This finding, along with the
lack of difference in UACR between the
DAA+/IR and the two IS groups, suggest a
threshold effect of IR on the magnitude of
albuminuria. Our study design imposes a
logical yet arbitrary cutpoint for IR to de-
fine the four diabetes etiologic groups.
Future studies exploring the shape of
the relationship between insulin sensi-
tivity and UACR are needed to clarify
their relationship.
We are not the first to find an asso-
ciation between the degree of insulin
resistance and the degree of albuminuria
(26–28). The components of metabolic
syndrome have long been identified as
risk factors for albuminuria, even in the
absence of diabetes (27,29). Recently,
several theories have been proposed re-
garding the mechanisms with which in-
sulin resistance could lead to albuminuria
as well as other microvascular and macro-
vascular complications (30–32). Visceral
adipose tissue is unique in its ability to
function as a metabolic and endocrino-
logic organ (32). Macrophage infiltration
and adipokine production result in an in-
flammatory and hormonal cascade that
has been found to have direct effects on
endothelial and podocyte functions
within the glomerulus (30,31,33). More-
over, in the presence of adipokines, po-
docytes have been noted to develop
altered insulin signaling that renders
them more susceptible to apoptosis, lead-
ing to albuminuria (30,31). It is also im-
portant to consider that the relationships
of diabetic nephropathy lesions and albu-
minuria are more complex in type 2 ver-
sus type 1 diabetes. A substantial subset of
microalbuminuric type 2 patients may
have glomerular structural parameters in
the normal range, whereas this is rare
among type 1 patients (34). Thus, the
prognostic significance of the albumin-
uria findings in the current study will re-
quire long-term follow-up.
There are several limitations to our
study. Most importantly, we collected only
a single random urine specimen. Ortho-
static proteinuria is fairly common in
children, as is intraindividual variation in
UACR (35,36). However, both of these sit-
uationswould result in nondifferentialmis-
classification, which would bias the results
toward the null hypothesis. Another limi-
tation is the use of only two antibodies,
IA-2A and GADA, for identification of
autoimmune-mediated diabetes. Recently,
autoantibodies to zinc transporter 8 have
been identified in the pathogenesis of
type 1 diabetes (37). Although there are
plans to measure this autoantibody in
SEARCH, it is not yet available. This could
have resulted in misclassification in the
DAA2/IR group; however, again, this
would bias our results toward the null
hypothesis. In addition, we estimated in-
sulin sensitivity rather than measuring it
with the euglycemic-hyperinsulinemic
clamp. Euglycemic-hyperinsulinemic
clamp studies are impractical for use
in a large cohort of children because of
the invasiveness and high cost. Our esti-
mating equation was developed and
validated in a subset of 85 SEARCH partic-
ipants and 22 nondiabetic controls who
underwent euglycemic-hyperinsulinemic
clamp study and was found to explain
74% of the variance of glucose disposal
rate (21). This is superior to a previously
published estimating equation that used
only 24 participants and found their equa-
tion to explain 57% of the variance in glu-
cose disposal rate (38). We defined insulin
resistance using an arbitrary cutpoint of the
25th percentile in the insulin sensitivity
score in nondiabetic children. Previously,
we performed sensitivity analyses using
higher and lower cutpoints of the IS score
and found the groups to be extremely sim-
ilar (22).
Strengths of our study include the
large sample size and ethnic and geo-
graphic diversity of the SEARCH cohort,
which make our findings very general-
izable. Moreover, SEARCH is a unique and
valuable resource because it includes youth
with newly diagnosed type 1 and type 2
diabetes. No other study has had the capa-
bility to explore the impact of insulin re-
sistance on microvascular complications
across the diabetes etiologic spectrum in a
pediatric population.
In summary, using a novel approach
to etiologic classification of diabetes type,
we have been able to explore the associ-
ation of diabetes etiologic subgroups with
the severity of albuminuria in newly di-
agnosed youth with diabetes. Our results
suggest that rather than the presence of
diabetes autoimmunity, it may be the se-
verity of insulin resistance that more
strongly associates with albuminuria. This
finding increases the urgency for investiga-
tors to determine the pathogenesis and
prognostic significance of albuminuria in
these young diabetic patients, and for
clinicians and public health experts to
address the overweight and obesity epi-
demic in youth. Further analyses of the
spectrum of insulin resistance and thresh-
olds that may increase the risk for diabetic
kidney disease are warranted.
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